Medullary carcinoma of the thyroid chemotherapy

Thyroid Cancer (Second Edition): A Comprehensive Guide to Clinical Management

Volumn , Issue , 2006, Pages 609-611

  Lessin, Lawrence S ^a,b  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880105130     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-995-0_76     Document Type: Chapter

References (23)

1. Gottlieb JA, Hill CS. Chemotherapy of thyroid cancer with Adriamycin: experience with 30 patients. N Engl J Med 1974; 290:193-197.
2. Benker G, Reinwein D. Ergegnisse der Chemotherapie des Schild-drusenkarzinoms. Dtsch Med Wochenschr 1983; 11:403-406.
3. DeBesi P, Busnardo B, Toso S, et al. Combined chemotherapy with bleomycin, Adriamycin and platinum in advanced thyroid cancer. J Endocrinol Invest 1991; 14:475-480.
4. Scherubl H, Rane F, Ziebler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. J Cancer Res Clin Oncol 1990; 116:21-23.
5. Athanassiades P, Piperingos G, Pandos P, et al. Serial serum calcitonin concentrations to evaluate response to therapy of patients with medul-larty thyroid carcinoma. Chemioterapia 1988; 7:195-197.
6. Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metasta-tic non-anaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990; 76:480-483.
7. Porter AT, Ostrowski MJ. Medullary carcinoma of the thyroid treated by low-dose Adriamycin. Br J Clin Pract 1990; 44:517-518.
8. Massart C, Gibassier J, Raoul M, et al. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anti-cancer Drugs 1995; 6:135-146.
9. Hoskin PJ, Harmer C. Chemotherapy for thyroid cancer. Radiother Oncol 1987; 10:187-194.
10. Kelsen D, Fiore J, Heelan R, et al. Phase II trial of etoposide in APUD tumors. Cancer Treatm Rep 1987; 71:305-307.
11. Sigurdur R, Petursson. Metastatic medullary thyroid carcinoma complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 1988; 62:1899-1903.
12. Burgess MA, Sellin RV, Gagel RF. Chemotherapy for medullary carcinoma of the thyroid with doxorubicin, imadazole carboximide, vincristine and cyclophosphamide. Proc Annu Meet Am Soc Clin Oncol 1995; 14:417.
13. Nocera M, Baudin E, Pellegriti G, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 2000; 83:715-718.
14. Muller OA, Landgraf R, Zeigler R, Scariba PC. Effects of somatostatin on calcitonin and ectopic ACTH release in a patient with medullary thyroid carcinoma. Acta Endocrinol 1977; 84(Suppl):49-50.
15. Mahler C, Verhelst J, DeLongueville M, Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 1990; 33: 261-269.
16. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000; 85:983-988.
17. Shimaoka K, Schoenfeld D, De Wys W, et al. A randomized trial of doxorubicin vs doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155-2160.
18. Droz JP, Rougier P, Goddefroy V, et al. Chemotherapy for medullary cancer of thyroid: phase II trials with adriamycin and cisplat-inum administered as monochemotherapy. Bull Cancer 1984; 71: 195-199.
19. Frame J, Kelsen D, Kemeny N, et al. A phase II trial of streptozotocin and Adriamycin in advanced APUD tumors. Am J Clin Oncol 1988; 11:490-495.
20. Stein R, Chen S, Reed L, et al. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma; effectiveness of dacarbazine. Cancer 2002; 94:51-61.
21. Cohen MS, Hussain HB, Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002; 132:960-966.
22. Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol 2003; 4:339-347.
23. Skinner MA, Safford SD, Freemerman AJ. RET tyrosine kinase and medullary thyroid cells are unaffected clinical doses of ST1571. Anticancer Res 2003; 23:3601-3606.